Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
IDEXX Laboratories Inc(IDXX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IDXX
10/14/2026: IDXX (1-star) is currently NOT-A-BUY. Pass it for now.
IDEXX Laboratories is a leading global provider of diagnostic and software solutions, primarily serving the companion animal healthcare market. The company benefits from a high-quality, 'razor-and-blade' business model characterized by recurring revenue from diagnostic reagents and a broad installed base of equipment. Its primary growth story remains the long-term trend of increasing pet humanization and the resulting higher spending on preventative animal care. While IDEXX maintains a robust market position, risks include a premium valuation, consolidation among its veterinary clinic customers, and increased competition from integrated life-science peers. Investors should monitor the company's success in software adoption and its ability to innovate in AI-driven diagnostics.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company has a history of high revenue growth driven by secular trends in pet humanization and diagnostic adoption. |
| Momentum investor | Mixed fit | Stock performance is strong but often sensitive to valuation multiples, making entry points crucial. |
| Value investor | Weak fit | The stock typically trades at a premium valuation multiple due to its growth profile and business quality. |
| Dividend investor | Weak fit | IDEXX does not pay a cash dividend, focusing instead on reinvesting earnings into the business. |
| Low-risk investor | Mixed fit | While the business model is recurring and high-quality, the stock can experience significant price volatility related to valuation. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock's valuation premium can lead to sharp price swings based on quarterly results or broader market sentiment. |
| Valuation risk | High | Trading at a high P/E ratio leaves little room for error regarding earnings growth expectations. |
| Competition risk (Consolidation/Pharma integration) | Medium | Competitors like Zoetis, which bundle diagnostics with pharmaceuticals, could pressure IDEXX's market share. |
| Business quality | Strong | The company maintains a high-moat business with significant recurring revenue and high customer retention. |
| Dividend income | Low / none | Investors seeking immediate cash flow will not find it with this growth-focused stock. |
| Execution risk | Low | The company has a long track record of successfully scaling operations and integrating new technologies. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 26.66% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/14/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 40.99B USD | Price to earnings Ratio 36.56 | 1Y Target Price 701.33 |
Price to earnings Ratio 36.56 | 1Y Target Price 701.33 | ||
Volume (30-day avg) 520.8K shares | Beta 1.55 | 52 Weeks Range 500.61 - 769.98 | Updated Date 10/14/2026 |
52 Weeks Range 500.61 - 769.98 | Updated Date 10/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 14.23 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Companion Animal Group (CAG) | Point-of-care instruments, rapid tests, reference labs, and software. | The primary engine of growth, generating recurring revenue as clinics use these tests daily. |
| Water Quality | Microbiology testing for water safety. | Provides a steady, non-cyclical revenue stream linked to regulatory and safety standards. |
| Livestock, Poultry and Dairy | Disease monitoring and herd health testing. | A more cyclical segment tied to the health of global production animal populations. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 36.56 | Forward PE 31.45 | Enterprise Value 41.98B | Price to Sales(TTM) 9 |
Enterprise Value 41.98B | Price to Sales(TTM) 9 | ||
Enterprise Value to Revenue 9.22 | Enterprise Value to EBITDA 25.98 | Shares Outstanding 78.78M | Shares Floating 78.47M |
Shares Outstanding 78.78M | Shares Floating 78.47M | ||
Percent Insiders 0.22 | Percent Institutions 96.64 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.